Showing 673–688 of 970 results
Assess NK cell inhibition, lymphocyte differentiation (CD markers), NK cell toxicity, and TH1/TH2 cytokines to evaluate immune status and function.
Sample Type : Special Tubes
Methodology : NA
TAT : 15 Days
Sample Type : Dry Swab / Urine
Methodology : Real-time PCR
TAT : 1 Day
Sample Type : Serum
Methodology : Trace Assay
TAT : 15 Days
Sample Type : Serum
Methodology : Immunofluorescence
TAT : 10 Days
Sample Type : Whole Blood
Methodology : Enzyme-immunoassay
TAT : 15 Days
Sample Type : Urine
Methodology : Chemiluminescence
TAT : 15 Days
The Oncomine Comprehensive Myeloid/Leukemia Panel (DNA + RNA fusions) is a next-generation sequencing (NGS) assay designed for comprehensive genomic profiling of myeloid malignancies and leukemias. It simultaneously analyzes DNA and RNA to detect key mutations, copy number variations, and gene fusions across a broad range of clinically relevant genes.